Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher

Weight loss drugs are already taking a bite out of many people’s wallets.

Fortune

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

The Independent UK

Hims Stock Claws Back After Novo Nordisk Undercuts It With A Cheaper Wegovy

Novo Nordisk slashed the price of Wegovy by more than half on Wednesday amid a bitter rivalry with Hims & Hers Health.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Weight-loss jab use rising among people with eating disorders, experts warn as NHS chief calls for crackdown

Online pharmacies and private providers have been urged to ‘act responsibly’ and ensure that the drugs are only prescribed to people with a medical need

The Independent UK

Class of 2025: Meet the 12 British cyclists who turned pro this year

A bounteous 12 Brits have stepped up to the pro ranks in 2025. Tom Davidson traces the skyward trajectories of a former runner, an adoptive Italian, and the WorldTour’s youngest rider

Cycling Weekly

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a setback.

Investors Business Daily

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Why IBD 50's Top Seed, Hims & Hers, Just Crashed On Its Upbeat Earnings

Hims stock plunged Tuesday after the compounding pharmacy issued a bullish outlook that still includes knockoff versions of semaglutide.

Investors Business Daily

Weight loss drugs linked to dozens of deaths

The medical director of the NHS has warned of the side effects of weight loss drugs after figures revealed the number of deaths associated with the jabs

The Independent UK

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.

Investors Business Daily

These 3 Stocks Just Announced Major Dividend Hikes

See which three stocks just raised their dividend payments by over 15%. On firm now has a sky-high indicated yield of over 10%.

MarketBeat

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?

MarketBeat

Novo Nordisk reprimanded for allegedly failing to disclose payments

The manufacturer of the weight loss jab Wegovy said it ‘is dedicated to working transparently and ethically’.

Evening Standard

Ozempic Blindness Lawsuit Mounts: Shocking Side Effect Of Weight Loss Drug Is 'Eye Stroke,' What You Need To Know

Warnings from experts indicate Ozempic and similar drugs such as Wegovy and Mounjaro can cause the critical medical condition' eye stroke', which results in permanent blindness.

International Business Times UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why

There’s no direct link between vision loss and taking the weight loss and diabetes drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound. But, a small percentage of patients are experiencing it

The Independent UK

Advertising regulator launches nine investigations into weight loss jab ads

Exclusive: ASA calls number of parallel probes ‘significant’ and describes tackling issue as ‘priority’ after it issued warning to advertisers for drugs including Ozempic and Wegovy

Fortune

Ozempic, Wegovy maker claps back at Hims & Hers Super Bowl ad: ‘Check before you inject’

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Investors Business Daily

Stock Market Sideways Amid Trump Tariff, Inflation Fears; Palantir, Google, Amazon Among Key Movers: Weekly Review

The stock market was up and down with Trump tariff fears in focus. Palantir led big earnings winners. Google and Amazon were losers.

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune

Novo Nordisk missed its diversity targets last year. Its CEO paid the price

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI targets.

Investors Business Daily

Novo Surges As Ozempic Drives Fourth-Quarter Beat. But Supply Shortages Expected.

Novo Nordisk stock reversed a three-day downtrend Wednesday after the weight-loss drugs kingpin leaned on Ozempic for a fourth-quarter beat.

The Guardian - UK

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

Fortune

Novo Nordisk CFO says drugmaker focusing on next generation of weight loss drugs

Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.

Evening Standard

Wegovy obesity drug sales more than double but set to slow

Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year.

The Independent UK

Wegovy: sales of weight loss injection more than double

The company said more than 45 million people were now ‘benefitting from our treatments’

1 2 3 4 5

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.